GSK to Work with Valeant on Epilepsy Drug
After a year of layoffs and restructuring, Valeant Pharma scores big with a collaboration deal worth up to $670 million.
UCB Pharma to Rebrand as Specialty Company
The Belgium-based drug maker is terminating 2,000 jobs and rebranding itself as a biopharm with a focus on CNS and immunology drugs. Pharm Exec gave UCB a call to find out more.
